Welcome to our dedicated page for Syros Pharmaceut news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceut stock.
Syros Pharmaceuticals, Inc. (SYRS) is a pioneering life sciences company dedicated to transforming the treatment landscape for various diseases by strategically mapping gene regulatory circuits and modulating the factors that control gene expression. Syros stands out in the pharmaceutical industry for its groundbreaking gene control research and drug discovery capabilities, which integrate disease biology and genomic data in ways that are not commonly seen in traditional pharmaceutical R&D.
At the heart of Syros' innovative approach is a proprietary platform composed of advanced assay technologies, sophisticated bioinformatics, and deep biological insights. This platform, developed by Syros' seasoned senior leadership team, is designed to decode the complexities of gene regulation and uncover new therapeutic avenues.
While the scientific approach of Syros has broad applications across multiple therapeutic areas, the company has achieved notable success in oncology. Syros is working to address significant unmet medical needs, particularly in the treatment of hematologic malignancies, by developing new standards of care for frontline patient treatment.
Syros Pharmaceuticals is currently involved in several promising projects and partnerships aimed at advancing its clinical pipeline and expanding its impact on patient care. The company’s recent achievements and ongoing projects underscore its commitment to harnessing gene control research to develop innovative therapies.
Financially, Syros is strategically positioned to continue its research and development efforts, supported by robust funding and a clear vision for the future of precision medicine. With a focus on oncology, Syros continues to push the boundaries of what is possible in medical science, aiming to deliver groundbreaking treatments that can significantly improve patient outcomes.
Syros Pharmaceuticals (SYRS) reported its Q2 2021 financial results, showing revenues of $5.2 million, up from $3.2 million in Q2 2020. The net loss was $22.5 million, or $0.36 per share. Cash, cash equivalents, and marketable securities totaled $195.3 million as of June 30, 2021. The company is advancing its portfolio in targeted hematology and selective CDK inhibition, with significant milestones including collaborations with Roche for SY-5609, a selective CDK7 inhibitor. Upcoming trials are set to begin in the second half of 2021, indicating a strong focus on addressing unmet medical needs.
Syros Pharmaceuticals (NASDAQ:SYRS) has established a clinical supply agreement with Roche to provide SY-5609, an oral CDK7 inhibitor, for a combination therapy study in Roche's Phase 1/1b INTRINSIC trial. This trial targets colorectal cancer patients and explores SY-5609's efficacy in conjunction with atezolizumab. Roche will sponsor the study and cover associated costs, while Syros retains rights to SY-5609 and will have access to study data. Previous preclinical studies suggest that SY-5609 may significantly enhance the effectiveness of immunotherapy in BRAF-mutant colorectal cancer.
Syros Pharmaceuticals (NASDAQ:SYRS) will host a live conference call and webcast on August 5, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 financial results and provide a corporate update. Interested parties can join the call by dialing 866-595-4538 domestically or 636-812-6496 internationally, using conference ID 4156527. The call can also be accessed via the Syros website, with a replay available for 30 days post-event. Syros is focused on developing innovative gene expression control therapies for cancer and other serious diseases.
Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities 2021 Life Sciences Conference on June 16 at 1:00 p.m. ET. A live webcast will be available on the Syros website, with an archived replay accessible for 30 days post-event. Syros focuses on innovative gene expression control with a robust clinical pipeline, including SY-1425 for myelodysplastic syndrome, SY-2101 for acute promyelocytic leukemia, and SY-5609 for solid tumors.
Syros Pharmaceuticals (NASDAQ:SYRS) announced a three-part KOL webcast series focusing on its investigational targeted therapies in hematology. The series will cover SY-1425 for myelodysplastic syndrome and acute myeloid leukemia, along with SY-2101 for acute promyelocytic leukemia. Presentations will feature Syros leaders and guest KOLs, highlighting recent advancements and unmet needs in these diseases. Webcasts are scheduled for May 26, June 22, and July 20, 2021, each starting at 8:30 AM ET. Archived replays will be available post-event.
Syros Pharmaceuticals (NASDAQ:SYRS) reported Q1 2021 financial results, showing revenues of $4.8 million, up from $2.4 million in Q1 2020. The company is progressing in hematology with a Phase 3 trial of SY-1425 for RARA-positive higher-risk MDS, and planning to initiate further trials for SY-1425 and SY-2101 in H2 2021. R&D expenses increased to $20.0 million due to clinical advancements, while G&A expenses rose to $5.7 million. Net loss decreased to $14.2 million, or $0.23 per share. Cash reserves stood at $222.1 million, expected to fund operations through 2023.
Syros Pharmaceuticals (NASDAQ:SYRS) will host a live conference call and webcast on May 6, 2021, at 8:30 a.m. ET to discuss its first-quarter financial results and provide a corporate update. Investors can join the call by dialing 866-595-4538 domestically or 636-812-6496 internationally, using conference ID 5770919. The event will also be available via webcast on their website, with an archive accessible for 30 days post-event. Syros is focused on gene expression control and has a strong clinical pipeline, including SY-1425 for myelodysplastic syndrome and SY-2101 for acute promyelocytic leukemia.
Syros Pharmaceuticals (SYRS) reported financial results for Q4 and the full year 2020, achieving revenues of $5.7 million in Q4 and $15.1 million for the year. The net loss for Q4 was $30.1 million ($0.62 per share), compared to $19.7 million in Q4 2019. Cash and equivalents stood at $174 million as of December 31, 2020. The company announced significant advancements in its clinical programs, including initiating Phase 2 trials for SY-1425 in AML and SY-2101 in APL. Syros expects to continue funding its operations through 2023 with its current cash position.
Syros Pharmaceuticals (NASDAQ:SYRS) will host a live conference call and webcast on March 4, 2021, at 8:30 a.m. ET to discuss its fourth quarter and full year 2020 financial results. Investors can dial 866-595-4538 for domestic or 636-812-6496 for international access, using conference ID 4472467. A replay will be available for 30 days post-event. Syros is focused on developing treatments that modulate gene expression, with a clinical-stage pipeline that includes innovative therapies like SY-1425 for myelodysplastic syndrome and SY-5609 for solid tumors.
Syros Pharmaceuticals (NASDAQ:SYRS) announces participation in three investor conferences. The Cowen and Company 41st Annual Health Care Conference on March 1 will feature a panel titled Novel Oncology Targets at 1:20 p.m. ET. The 33rd Annual Roth Conference on March 15 will discuss Navigating Clinical Development in RARE Hematologic & Inflammatory Disease at 10:00 a.m. ET. Lastly, the Oppenheimer 31st Annual Healthcare Conference will occur on March 16, starting at 8:40 a.m. ET. Live webcasts will be available on the Syros website.
FAQ
What is the current stock price of Syros Pharmaceut (SYRS)?
What is the market cap of Syros Pharmaceut (SYRS)?
What does Syros Pharmaceuticals specialize in?
What is unique about Syros Pharmaceuticals' approach?
In which therapeutic areas has Syros Pharmaceuticals shown success?
What recent achievements has Syros Pharmaceuticals made?
What is the financial condition of Syros Pharmaceuticals?
What is the proprietary platform of Syros Pharmaceuticals?
How does Syros Pharmaceuticals impact patient treatment?
Where is Syros Pharmaceuticals making its mark in the pharmaceutical industry?
Who are the key contributors to Syros Pharmaceuticals' proprietary platform?
What is the mission of Syros Pharmaceuticals?
